Amiloidosis Asociada a Hemodiálisis: Revisión Literaria
PDF

Palabras clave

Amiloidosis, Enfermedad Renal Crónica, Hemodiálisis, βeta-2-Microglobulina (DeSC).

Cómo citar

1.
Bohórquez-Rivero J, Sanchez-Martínez D, Brieva-Deulofeut M, Sáenz-López J, Restom-Arrieta J, Abuabara-Franco E. Amiloidosis Asociada a Hemodiálisis: Revisión Literaria. Rev. Colomb. Nefrol. [Internet]. 19 de marzo de 2021 [citado 21 de octubre de 2021];8(2):e511. Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/511

Resumen

La amiloidosis constituye una complicación importante en los pacientes con enfermedad renal crónica terminal que son sometidos a hemodiálisis durante extensos períodos de tiempo. Al igual que en otras amiloidosis sistémicas, la amiloidosis asociada a hemodiálisis está formada por diferentes sustancias, algunas de ellas de carácter fibrilar, como la ?eta-2-microglobulina, la cual representa una de las proteínas de mayor relevancia dada su implicación etiopatogénica. A pesar de que las técnicas de hemodiálisis han sido mejoradas con el paso de los años, dicha entidad continúa siendo una complicación relativamente frecuente; tal es que se puede presentar hasta en el 80% de los pacientes con hemodiálisis prolongadas. Por lo tanto, se hizo imprescindible realizar una revisión narrativa partiendo de la literatura científica disponible en las diferentes bases de datos con el objetivo de contribuir a mejorar y actualizar el conocimiento del médico en dicho tópico; abarcando desde los aspectos generales y su fisiopatología, hasta su presentación clínica, diagnóstico, y tratamiento.

https://doi.org/10.22265/acnef.8.2.511
PDF

Citas

1. Nishi S, Alchi B, Imai N, Gejyo F. New advances in renal amyloidosis. Clin Exp Nephrol [Internet]. 2008;12(2):93–101.
2. Heininger D. Renal aspects of amyloidosis. Memo - Mag Eur Med Oncol [Internet]. 2012;5(1):11–4.
3. Nishi S, Alchi B, Imai N, Gejyo F. New advances in renal amyloidosis. Clin Exp Nephrol [Internet]. 2008;12(2):93–101.
4. Leung N. DSMA Renal Scan in Cardiac Amyloidosis: Are We Missing Something? Mayo Clin Proc [Internet]. 2019;94(6):936–8.
5. Takahashi N, Glockner J, Howe BM, Hartman RP, Kawashima A. Taxonomy and Imaging Manifestations of Systemic Amyloidosis. Radiol Clin North Am [Internet]. 2016;54(3):597–612. Available from: http://dx.doi.org/10.1016/j.rcl.2015.12.012
6. Magro Checa C, Rosales Alexander JL, Salvatierra J, Raya Álvarez E. Amyloidosis. Med [Internet]. 2013;11(34):2065–75. Available from: https://bibliotecavirtual.unisinu.edu.co:2095/#!/content/journal/1-s2.0-S030454121370581X?scrollTo=%23hl0000662
7. Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch [Internet]. 2002;440(2):111–22.
8. Gejyo F. Clinical and pathogenic factors in dialysis-related amyloidosis: Current research findings. Osteoporos Int [Internet]. 1997;7(SUPPL. 3).
9. Oyarzábal MVI, López Lasanta M, Ureña Garnica I, Fernández-Nebro A. Amyloidosis. Medicine (Baltimore) [Internet]. 2009;10(33):2185–91.
10. Taffel MT, Nikolaidis P, Beland MD, Blaufox MD, Dogra VS, Goldfarb S, et al. ACR Appropriateness Criteria®? Renal Transplant Dysfunction. J Am Coll Radiol [Internet]. 2017;14(5):S272–81. Available from: http://dx.doi.org/10.1016/j.jacr.2017.02.034
11. Sarac E. Treatment of Peripheral Neuropathy Associated With Dialysis Related Amyloidosis. Am J Kidney Dis [Internet]. 2016;67(5):A94. Available from: https://bibliotecavirtual.unisinu.edu.co:2095/#!/content/journal/1-s2.0-S0272638616005254
12. Santoro A, Mancini E, Bolzani R, Boggi R, Cagnoli L, Francioso A, et al. The Effect of On-line High-flux Hemofiltration Versus Low-flux Hemodialysis on Mortality in Chronic Kidney Failure: A Small Randomized Controlled Trial. Am J Kidney Dis [Internet]. 2008;52(3):507–18. Available from: https://bibliotecavirtual.unisinu.edu.co:2095/service/content/pdf/watermarked/1-s2.0-S0272638608008883.pdf?locale=es_ES&searchIndex=
13. Gupta N, Kaur H, Wajid S. Renal amyloidosis: an update on diagnosis and pathogenesis. Protoplasma [Internet]. 2020; Available from: https://bibliotecavirtual.unisinu.edu.co:2318/article/10.1007/s00709-020-01513-0
14. Liu, C., Sawaya, M. & Eisenberg, D. ?2-microglobulin forms three-dimensional domain-swapped amyloid fibrils with disulfide linkages. Nat Struct Mol Biol 18, 49–55 (2011). https://doi.org/10.1038/nsmb.1948
15. Morris AD, Smith RN, Stone JR. The pathology and changing epidemiology of dialysis-related cardiac beta-2 microglobulin amyloidosis. Cardiovasc Pathol [Internet]. 2019;42(2019):30–5. Available from: https://doi.org/10.1016/j.carpath.2019.05.002
16. Yamamoto S, Kazama JJ, Narita I, Naiki H, Gejyo F. Recent progress in understanding dialysis-related amyloidosis. Bone [Internet]. 2009;45(SUPPL. 1):S39–42. Available from: http://dx.doi.org/10.1016/j.bone.2009.03.655
17. Díaz González A, Rodríguez Pérez JC: Estado actual de la amiloidosis asociada a diálisis. Nefrología 18: 443448, 1998. 12.
18. Monge-Berruezo MI, Acal Gutiérrez P, Benavente Valdepeñas AM, Giménez García JM, Sánchez García MD, Acal-Gutiérrez J. Amiloidosis asociada a hemodiálisis como causa de subluxación atlo-axoidea anteriorRehabilitación (Madr) 2003;37(3):166-9.
19. Bhat A, Selmi C, Naguwa SM, Cheema GS, Gershwin ME. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol [Internet]. 2010;38(2–3):97–106. Available from: https://bibliotecavirtual.unisinu.edu.co:2318/content/pdf/10.1007/s12016-009-8163-9.pdf
20. Sumi Y, Hayashi Y, Hattori H, Ueda M. Dialysis-related amyloidosis of the temporomandibular joint. Int J Oral Maxillofac Surg [Internet]. 2005;34(6):696–8. Available from: https://bibliotecavirtual.unisinu.edu.co:2106/science/article/pii/S0901502704003236
21. Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant ?2-microglobulin. N Engl J Med. 2012;366(24):2276-2283. doi:10.1056/NEJMoa1201356. Available from: https://pubmed.ncbi.nlm.nih.gov/22693999/
22. Vieira WP, Gomes KWP, Frota NB, Andrade JECB, Vieira RMR de A, Moura FEA, et al. Manifestações musculoesqueléticas em pacientes submetidos à hemodiálise. Rev Bras Reumatol [Internet]. 2005;45(6):357–64. Available from: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042005000600005&lng=pt&nrm=iso&tlng=pt
23. M’Bappe P, Grateau G. Manifestaciones osteoarticulares de la amiloidosis. EMC - Apar Locomot [Internet]. 2015;48(3):1–10. Available from: http://dx.doi.org/10.1016/S1286-935X(15)72883-2
24. Sigaux J, Abdelkefi I, Bardin T, Laredo JD, Ea HK, UreñaTorres P, et al. Tendon thickening in dialysis-related joint arthritis is due to amyloid deposits at the surface of the tendon. Jt Bone Spine [Internet]. 2019;86(2):233–8. Available from: https://bibliotecavirtual.unisinu.edu.co:2095/service/content/pdf/watermarked/1-s2.0-S1297319X18303075.pdf?locale=es_ES&searchIndex=
25. Chiang ER, Chen KH, Wang ST, Ma HL, Chang MC, Liu CL, et al. Intra-articular Injection of Tranexamic Acid Reduced Postoperative Hemarthrosis in Arthroscopic Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Study. Arthrosc - J Arthrosc Relat Surg [Internet]. 2019;35(7):2127–32. Available from: https://doi.org/10.1016/j.arthro.2019.02.018
26. Chen H, Yuan A. Prolotherapy treatment for Dequervain’s Tenosynovitis and Intersection Syndrome. J Pain [Internet]. 2015;16(4):S113. Available from: http://dx.doi.org/10.1016/j.jpain.2015.01.469
27. Shinohara T, Tatebe M, Okui N, Yamamoto M, Kurimoto S, Hirata H. Cubital tunnel syndrome caused by amyloid elbow arthropathy in long-term hemodialysis patients: Report of 4 cases. J Hand Surg Am [Internet]. 2011;36(10):1640–3. Available from: http://dx.doi.org/10.1016/j.jhsa.2011.07.009
28. Schaeffer J, Floege J, Ehlerding G, Koch KM. Pathogenetic and diagnostic aspects of dialysis-related amyloidosis. Nephrol Dial Transplant. 1995;10 Suppl 3:4-8. doi:10.1093/ndt/10.supp3.4
29. Matsuo K, Ikizler TA, Hoover RL, Nakamoto M, Yasunaga C, Pupim LB, et al. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Kidney Int. 2000;57(2):697-708. doi:10.1046/j.1523-1755.2000.00892.x
30. Scarpioni R, Ricardi M, Albertazzi V, De Amicis S, Rastelli F, Zerbini L. Dialysis-related amyloidosis: challenges and solutions. Int J Nephrol Renovasc Dis. 2016;9:319-328. Published 2016 Dec 7. doi:10.2147/IJNRD.S84784
31. Schiffl H. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients. Hemodial Int. 2014;18(1):136-141. doi:10.1111/hdi.12057
32. Mourad G, Argilés A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol. 1996;7(5):798-804.
33. Sethi D. Dialysis-associated amyloidosis. Ren Fail. 1993;15(3):349-351. doi:10.3109/08860229309054943
34. Fukuda K, Yamamoto H. Dialysis-related amyloidosis. Semin Musculoskelet Radiol. 2001;5(2):113-119. doi:10.1055/s-2001-15879
35. Santagati G, Cataldo E, Columbano V, Chatrenet A, Penna D, Pelosi E, et al. Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis. J Clin Med. 2019;8(9):1494. Published 2019 Sep 19. doi:10.3390/jcm8091494
36. Miyata T, Inagi R, Kurokawa K. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis. Miner Electrolyte Metab. 1999;25(1-2):114-117. doi:10.1159/000057432
37. Naganuma T, Sugimura K, Uchida J, Tashiro K, Yoshimura R, Takemoto, et al. Increased levels of serum matrix metalloproteinase-3 in haemodialysis patients with dialysis-related amyloidosis. Nephrology (Carlton). 2008;13(2):104-108. doi:10.1111/j.1440-1797.2007.00845.x
38. Ishizaki M, Matsunaga T, Adachi K, Miyashita E. Serum matrix metalloproteinase-3 in hemodialysis patients with dialysis-related amyloidosis. Hemodial Int. 2004;8(3):219-225. doi:10.1111/j.1492-7535.2004.01099.x
39. Narang SS, Shuaib S, Goyal D, Goyal B. In silico-guided identification of potential inhibitors against ?2m aggregation in dialysis-related amyloidosis [published online ahead of print, 2019 Sep 27]. J Biomol Struct Dyn. 2019;1-15. doi:10.1080/07391102.2019.1668852
40. Kaneko S, Yamagata K. Hemodialysis-related amyloidosis: Is it still relevant?. Semin Dial. 2018;31(6):612-618. doi:10.1111/sdi.12720
41. Labriola L, Jadoul M. Dialysis-related Amyloidosis: Is It Gone or Should It Be?. Semin Dial. 2017;30(3):193-196. doi:10.1111/sdi.12590
42. Piccoli GB, Hachemi M, Molfino I, Coindre JP, Boursot C. Doxycycline treatment in dialysis related amyloidosis: Discrepancy between antalgic effect and inflammation, studied with FDG-positron emission tomography: A case report. BMC Nephrol [Internet]. 2017;18(1):1–6. Available from: https://bibliotecavirtual.unisinu.edu.co:2318/content/pdf/10.1186/s12882-017-0698-z.pdf
43. Hoshino J, Kawada M, Imafuku A, Mise K, Sumida K, Hiramatsu R, et al. A clinical staging score to measure the severity of dialysis-related amyloidosis. Clin Exp Nephrol [Internet]. 2017;21(2):300–6. Available from: https://bibliotecavirtual.unisinu.edu.co:2318/content/pdf/10.1007/s10157-016-1287-3.pdf
44. Camilleri B, Pararajasingam R, Buttigieg J, Halawa A. Renal transplantation in the elderly: Outcomes and recommendations. Transplant Rev [Internet]. 2020;34(2):100530. Available from: https://doi.org/10.1016/j.trre.2020.100530
45. Rodríguez Faba O, Boissier R, Budde K, Figueiredo A, Taylor CF, Hevia V, et al. European Association of Urology Guidelines on Renal Transplantation: Update 2018. Eur Urol Focus [Internet]. 2018;4(2):208–15.
46. Rocco M, Daugirdas JT, Depner TA, Inrig J, Mehrotra R, Rocco M V., et al. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. Am J Kidney Dis [Internet]. 2015;66(5):884–930.
47. Swift O, Vilar E, Farrington K. Haemodialysis. Med (United Kingdom) [Internet]. 2019;47(9):596–602.
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.

Derechos de autor 2021 Revista Colombiana de Nefrología

Descargas

Los datos de descargas todavía no están disponibles.